Skip to content

Clinical trials

Phase 2 Osteosarcoma trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Osteosarcoma Phase: Phase 2 Clear all

158 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20016
20022
20033
20044
20064
20077
20085
20097
20115
20123
20136
20147
20155
20166
201713
20187
20194
20207
20219
20226
20235
202412
20251
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed74
Recruiting21
Active, not recruiting20
Unknown status18
Terminated16
Not yet recruiting5
Withdrawn3
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)30
Memorial Sloan Kettering Cancer Center14
M.D. Anderson Cancer Center6
Children's Oncology Group5
Peking University People's Hospital5
St. Jude Children's Research Hospital5
Italian Sarcoma Group4
Sarcoma Alliance for Research through Collaboration4
Ruijin Hospital3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Osteosarcoma158
Sarcoma69
Rhabdomyosarcoma38
Neuroblastoma35
Neuroectodermal Tumors, Primitive, Peripheral35
Sarcoma, Ewing32
Wilms Tumor23
Medulloblastoma22
Hepatoblastoma21
Ependymoma17

Trials

Showing 76 to 100 of 158. Each trial links to its page on Pharma Observatory.

58 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.